EHA mapping of adolescent and young adult (AYA) hematology patient care

AdobeStock 476750341 AYA Survey

EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

AdobeStock 135134857

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

EHA welcomes European Parliament backing for SoHO legislation

AdobeStock 75539245

EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.

Read more

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and…


The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

More than science: the European Affairs program at EHA2023

1800 20220610

The ‘EU & Hematology track’ and other European Affairs activities at EHA2023 shed light on important regulatory developments and offer a platform for dialogue between hematologists, patients and other stakeholders.

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

SOHO EMA Image 1

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1   Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the…

Read more

EHA supports the proposal for a Regulation on the European Health Data Space (EH…

Healthcare stakeholders statement SM post

On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

Read more

EHA to the European Commission and HTA leaders: work with medical societies to i…

20220622 HTA Conference speakers

The speakers of the HTA conference hosted by the European Commission.

Read more

EU funding approved for TOLERATE

AdobeStock 68767205

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

EU pilot on drug repurposing

AdobeStock 276764998

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines.

Read more

EU Calls for Proposal 2022

AdobeStock 353450686

Introduction Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.…

Read more

EU Calls for proposal 2021

call for proposals cropped

Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year. Some of the most eye-catching initiatives are highly relevant for hematology: the Europe’s Beating Cancer Plan, the Pharmaceutical Strategy and the European Health Data Space.

Read more

EHA has joined the European Cancer Organisation - a perfect match on objectives …

Member Society badge 1501x1136

The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level. EHA’s membership application was approved by the General Assembly of the European Cancer Organisation on November 18, 2020.

Read more

Call for urgent action on medicine shortages in Europe

michal parzuchowski 7TWRwDjfGew unsplash

EPHA published a position paper on medicine shortages in Europe. EHA welcomes its  recommendations to address the increasing shortages crisis, which threatens patient outcomes and patient safety.

Read more

ATMPs and CAR-T: the uptake challenge

HemAffairs ATMPs and CAR T

Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?

Read more